Precigen (PGEN) to Release Earnings on Wednesday

Precigen (NASDAQ:PGEN) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $0.67 million for the quarter.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Precigen had a negative net margin of 3,728.87% and a negative return on equity of 279.20%. The business had revenue of $1.34 million for the quarter, compared to analysts’ expectations of $0.50 million. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Price Performance

Shares of PGEN stock opened at $1.74 on Tuesday. The company’s fifty day simple moving average is $1.62 and its two-hundred day simple moving average is $1.58. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17. The stock has a market capitalization of $513.61 million, a price-to-earnings ratio of -3.11 and a beta of 1.87.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 9,043 shares in the last quarter. AQR Capital Management LLC grew its position in Precigen by 216.9% in the first quarter. AQR Capital Management LLC now owns 63,179 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 43,245 shares in the last quarter. Strs Ohio purchased a new position in Precigen in the first quarter worth $70,000. Creative Planning grew its position in Precigen by 127.8% in the second quarter. Creative Planning now owns 94,291 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 52,901 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Precigen by 7.7% in the second quarter. Geode Capital Management LLC now owns 3,749,182 shares of the biotechnology company’s stock worth $5,325,000 after acquiring an additional 269,580 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PGEN has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Precigen in a report on Thursday, May 15th. JMP Securities restated a “market outperform” rating and set a $6.00 price target on shares of Precigen in a research report on Thursday, June 12th. Finally, Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.